Curt H. Hagedorn, M.D.

Research Interests

  • Hepatitis C
  • Liver Cancer
  • Epithelial Cancers

Languages

  • English

Academic Information

  • Departments: Internal Medicine - Adjunct Professor
  • Divisions: Gastroenterology
  • Cancer Center Programs: Nuclear Control of Cell Growth & Differentiation

Board Certification

  • American Board of Internal Medicine (Internal Medicine)

Academic Bio

Curt Hagedorn, MD, is an Adjunct Professor of Gastroenterology, Hepatology and Nutrition in the Department of Internal Medicine at the University of Utah School of Medicine. He is an investigator of the Huntsman Cancer Institute and a member of the Nuclear Control of Cell Growth and Differentiation program. He has extensive experience in treating patients with liver and other digestive diseases. He has done research that has been instrumental in developing new treatments for chronic hepatitis C to prevent liver cancer, and developed new approaches for identifying molecular diagnostic tests for premalignant digestive diseases.

Dr. Hagedorn received his M.D. degree from Washington University in St. Louis, Missouri in 1976, and completed a residency in Internal Medicine at Vanderbilt University Hospital in Nashville, Tennessee. He was a Clinical Associate in the Metabolism Branch at the National Cancer Institute at NIH which is renowned for conducting pioneering translational research that paves the way for new insights and treatments for human disease. Before joining the University of Utah, he was the Director of Gastroenterology/Hepatology at the Kansas University Medical Center where he was part of an interdisciplinary Pharmacology program that received a $10,000,000 NIH award to develop junior faculty careers in the study of liver diseases. Dr. Hagedorn was a Gastroenterology-Hepatology/Medicine faculty member and Cancer Center member at Emory University for eleven years where he also served as the Director of Hepatology and did work leading to new insights into hepatitis C and RNA biology.

Dr. Hagedorn’s medical science focus is inflammatory and premalignant conditions of the liver (e.g., hepatitis C) and GI tract. As a clinician-scientist Dr. Hagedorn leads a research team that has students, Univ. of Utah and overseas fellows, and faculty that are working on new antivirals for chronic hepatitis C and new approaches of identifying molecular diagnostics for serrated colon polyps that account for 20-30% of colon cancers. Dr. Hagedorn and his team have made critical contributions to the development of hepatitis C virus polymerase inhibitors that are currently in clinical trials. He has developed new ways of isolating gene products from clinical specimens to allow molecular studies of inflammatory premalignant GI diseases to be conducted. Such studies will provide insights into the molecular mechanisms of disease, identify new diagnostic/prognostic markers and new targets for therapies. Dr. Hagedorn receives funding from NIH and other agencies to conduct this work. He serves on several NIH study sections and on a USA FDA advisory panel. Dr. Hagedorn is the author of over 80 peer reviewed articles, is Associate Editor for the journal Viruses and is a regular speaker at international conferences.

Education History

Type School Degree
Fellowship Barnes Hospital
Gastroenterology
Fellow
Fellowship National Institutes of Health
Medical Science
Fellow
Residency Vanderbilt University Hospital
Internal Medicine
Resident
Internship Vanderbilt University Hospital
Internal Medicine
Intern
Professional Medical Washington University
Medicine
M.D.
Graduate Training Robert Wood Johnson School of Medicine
Medicine
M.M.Sc.
Undergraduate Rutgers University
B.A.

Selected Publications

Journal Article

  1. IL-1beta Production through the NLRP3 Inflammasome by Hepatic Macrophages Links Hepatitis C Virus Infection with Liver Inflammation and Disease.Negash AA, Ramos HJ, Crochet N, Lau DT, Doehle B, Papic N, Delker DA, Jo J, Bertoletti A, Hagedorn CH, Gale M Jr (2013). IL-1beta Production through the NLRP3 Inflammasome by Hepatic Macrophages Links Hepatitis C Virus Infection with Liver Inflammation and Disease. PLoS Pathog, 9(4), e1003330.
  2. RNA-Sequencing Analysis of 5' Capped RNAs Identifies Many New Differentially Expressed Genes in Acute Hepatitis C Virus Infection.Papic N, Maxwell CI, Delker DA, Liu S, Heale BS, Hagedorn CH (2012). RNA-Sequencing Analysis of 5' Capped RNAs Identifies Many New Differentially Expressed Genes in Acute Hepatitis C Virus Infection. Viruses, 4(4), 581-612.
  3. Brennan BJ, Morcos PN, Wang K, Blotner SD, Morrison R, Hagedorn CH, Marbury TC, Sulkowski M, Grippo JF (2012). The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C. Aliment Pharmacol Ther, 35(10), 1209-1220.
  4. Role of nuclear receptor SHP in metabolism and cancer.Zhang Y, Hagedorn CH, Wang L (2011). Role of nuclear receptor SHP in metabolism and cancer. Biochim Biophys Acta, 1812(8), 893-908.
  5. ENCODE Tiling Array Analysis Identifies Differentially Expressed Annotated and Novel 5' Capped RNAs in Hepatitis C Infected Liver.Folkers ME, Delker DA, Maxwell CI, Nelson CA, Schwartz JJ, Nix DA, Hagedorn CH (2011). ENCODE Tiling Array Analysis Identifies Differentially Expressed Annotated and Novel 5' Capped RNAs in Hepatitis C Infected Liver. PLoS One, 6(2), e14697.
  6. Measuring antiviral activity of benzimidazole molecules that alter IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase.Liu S, Nelson CA, Xiao L, Lu L, Seth PP, Davis DR, Hagedorn CH (2011). Measuring antiviral activity of benzimidazole molecules that alter IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase. Antiviral Res, 89(1), 54-63.
  7. Genome-wide characterization of methylguanosine-capped and polyadenylated small RNAs in the rice blast fungus Magnaporthe oryzae.Gowda M, Nunes CC, Sailsbery J, Xue M, Chen F, Nelson CA, Brown DE, Oh Y, Meng S, Mitchell T, Hagedorn CH, Dean RA (2010). Genome-wide characterization of methylguanosine-capped and polyadenylated small RNAs in the rice blast fungus Magnaporthe oryzae. Nucleic Acids Res, 38(21), 7558-69.
  8. Further insights into the roles of GTP and the C terminus of the hepatitis C virus polymerase in the initiation of RNA synthesis.Harrus D, Ahmed-El-Sayed N, Simister PC, Miller S, Triconnet M, Hagedorn CH, Mahias K, Rey FA, Astier-Gin T, Bressanelli S (2010). Further insights into the roles of GTP and the C terminus of the hepatitis C virus polymerase in the initiation of RNA synthesis. J Biol Chem, 285(43), 32906-18.
  9. Human RNA polymerase III transcriptomes and relationships to Pol II promoter chromatin and enhancer-binding factors.Oler AJ, Alla RK, Roberts DN, Wong A, Hollenhorst PC, Chandler KJ, Cassiday PA, Nelson CA, Hagedorn CH, Graves BJ, Cairns BR (2010). Human RNA polymerase III transcriptomes and relationships to Pol II promoter chromatin and enhancer-binding factors. Nat Struct Mol Biol, 17(5), 620-8.
  10. Tsui, JI, Currie, S, Shen, H, Bini, EJ, Brau, N, Wright, TL, VA HCV-001 Study Group (2008). Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study. Dig Dis Sci, 53, 809-814.
  11. Cheung, RC, Currie, S, Shen, H, Bini, EJ, Ho, SB, Anand, BS, Hu, KQ, Wright, TL, Mogan, TR, VA HCV-001 Study Group (2008). Can We Predict the Degree of Fibrosis in Chronic Hepatitis C Patients Using Routine Blood Tests in Our Daily Practice? J Clin Gastroenterol, 42, 827-834.
  12. Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial.Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, Gillen DL, Gerner EW (2008). Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial. Cancer Prev Res Phila Pa, 1, 9-11.
  13. Complete genomes of three subtype 6t isolates and analysis of many novel hepatitis C virus variants within genotype 6.Lu L, Murphy D, Li C, Liu S, Xia X, Pham PH, Jin Y, Hagedorn CH, Abe K (2008). Complete genomes of three subtype 6t isolates and analysis of many novel hepatitis C virus variants within genotype 6. J Gen Virol, 89(Pt 2), 444-52.
  14. Efficient 5' cap-dependent RNA purification : use in identifying and studying subsets of RNA.Bajak EZ, Hagedorn CH (2008). Efficient 5' cap-dependent RNA purification : use in identifying and studying subsets of RNA. Methods Mol Biol, 419, 147-60.
  15. The unique HCV genotype distribution and the discovery of a novel subtype 6u among IDUs co-infected with HIV-1 in Yunnan, China.Xia X, Lu L, Tee KK, Zhao W, Wu J, Yu J, Li X, Lin Y, Mukhtar MM, Hagedorn CH, Takebe Y (2008). The unique HCV genotype distribution and the discovery of a novel subtype 6u among IDUs co-infected with HIV-1 in Yunnan, China. J Med Virol, 80(7), 1142-52.
  16. Hu KQ, Currie SL, Shen H, Cheung RC, Ho SB, Bini EJ, McCracken JD, Morgan T, Brau N, Schmidt WN, Jeffers L, Wright TL, VA HCV-001 Study Group (2007). Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans. Digestive Diseases and Sciences, 52, 570-8.
  17. Seal KH, Currie SL, Shen H, Anand BS, Bini EJ, Brau N, JeffersL, Wright TL, VA HCV-001 Study Group (2007). Hepatitis C treatment candidacy and outscomes among 4,31818 US veterans with chronic hepatitis C virus infection: does a history of injection drug use matter? Journal of Clinical Gastroenterology, 41, 199-205.
  18. Lu L, Li C, Fu Y, Gao F, Pybus OG, Abe K, Okamoto H, Hagedorn CH, Murphy D (2007). Complete genomes of hepatitis C virus (HCV) subtypes 6c, 6l, 6o, 6p and 6q: completion of a full panel of genomes for HCV genotype 6. Journal of General Virology, 88, 1519-25.
  19. Lu L, Li C, Fu Y, Thaikruea L, Thongswat S, Maneekarn N, Apichartpiyakul C, Hotta H, Okamoto H, Netski D, Pybus OG, Murphy D, Hagedorn CH, Nelson KE (2007). Complete genomes for hepatitis C virus subtypes 6f, 6i, 6j and 6m: viral genetic diversity among Thai blood donors and infected spouses. Journal of General Virology, 88, 1505-18.
  20. Puli SR, Singh S, Hagedorn CH, Reddy J, Olyaee M (2007). Diagnostic accuracy of EUS for vascular invasion in pancreatic and periampullary cancers: a meta-analysis and systematic review. Gastrointestinal Endoscopy, 65, 788-97.
  21. Eukaryotic initiation factor 4E variants alter the morphology, proliferation, and colony-formation properties of MDA-MB-435 cancer cells.Goldson TM, Vielhauer G, Staub E, Miller S, Shim H, Hagedorn CH (2007). Eukaryotic initiation factor 4E variants alter the morphology, proliferation, and colony-formation properties of MDA-MB-435 cancer cells. Molecular Carcinogenesis, 46(1), 71-84.

Book Chapter

  1. Bajak, E, Hagedorn, CH (2007). Efficient 5' cap dependent RNA purification: use in identifying and studying subsets of RNA. In J. Wilusz (Ed.), Methods in Molecular Biology, Post-transcriptional Regulation of Gene Expression. Humana Press, Inc.